Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

ClinicalTrials.gov ID: NCT02689284

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02689284. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This main purpose of this clinical study is to learn about the safety and activity of margetuximab and pembrolizumab combination treatment in patients with HER2+ gastric and gastroesophageal junction cancer.

Study identification

NCT ID: NCT02689284
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: MacroGenics; Industry
Enrollment: 95 participants

Conditions and interventions

Conditions

Interventions

Margetuximab 10 mg/kg Biological
Margetuximab 15 mg Biological
Pembrolizumab Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2016 (Actual)
Primary completion: Jan 2021 (Actual)
Completion: Jan 2021 (Actual)
Last update posted: Mar 17, 2025

2016 – 2021

United States locations

U.S. sites: 11
U.S. states: 11
U.S. cities: 11

Facility	City	State	ZIP	Site status
Yale School of Medicine	New Haven	Connecticut	06520	—
Georgetown University-Lombardi Comprehensive Cancer Center	Washington D.C.	District of Columbia	20007	—
University of Chicago	Chicago	Illinois	60637	—
Johns Hopkins University Medical Center	Baltimore	Maryland	21231	—
Dana-Farber Cancer Institute/Harvard University Medical Center	Boston	Massachusetts	02215	—
Karmanos Cancer Institute	Detroit	Michigan	48201	—
Washington University School of Medicine	St Louis	Missouri	63110	—
Duke University Medical Center	Durham	North Carolina	27710	—
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19107	—
Sarah Cannon Research Institute	Nashville	Tennessee	37203	—
Swedish Cancer Institute	Seattle	Washington	98104	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02689284, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 17, 2025 · Synced Nov 13, 2026